[EN] PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS [FR] DÉRIVÉS DE PYRIDAZINONE ET LEUR UTILISATION COMME INHIBITEURS DU RÉCEPTEUR P2X7
Use of N-Protected Amino Acids in the Minisci Radical Alkylation
摘要:
The Minisci radical alkylation has been demonstrated on a range of commercially available glycine derivatives and proceeds in good to high yield. When extending the reaction to other amino acids, competitive oxidation of the initially formed radical was overcome by using the phthalimide protecting group.
Pyridazinone compounds and P2X7 receptor inhibitors
申请人:Shigeta Yukihiro
公开号:US08440666B2
公开(公告)日:2013-05-14
Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.
PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS
申请人:Shigeta Yukihiro
公开号:US20100286390A1
公开(公告)日:2010-11-11
Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.
Disclosed in the present invention are a nitrogenous macrocyclic compound, a preparation method therefor, a pharmaceutical composition and an application thereof. The present invention provides a nitrogenous macrocyclic compound represented by formula III-0, a tautomer thereof, an optical isomer thereof, a hydrate thereof, a solvate thereof, a pharmacologically acceptable salt thereof, or a prodrug thereof. The compound can be effectively bond with bromodomains of a BET family: BRD4, BRD3, BRD2, and BRDT, so as to adjust transcription of a downstream gene c-myc and a related target gene thereof, and further to adjust a downstream signal path and play a particular role, comprising treating diseases such as inflammatory diseases, cancers, and AIDS.